A joint meeting of 2 FDA advisory panels is slated for next week to consider Avedro's corneal cross-linking therapy.
Avedro said today that it won a date with the FDA next week for its corneal cross-linking technology for treating a pair of eye conditions.
A joint meeting of the watchdog agency's Dermatologic & Ophthalmic Drugs Advisory Committee and its Ophthalmic Devices Panel is slated for Feb. 24, Boston-based Avedro said.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1EIT2BQ
Cap comentari:
Publica un comentari a l'entrada